Digital PCR Market: By Product Type (Reagents, Kits, and Consumables, Instruments, Software, Services), By Technology (Droplet Digital PCR (dPCR), BEAMing Digital PCR (dPCR)), By Application (Clinical Diagnostics, Life Science Research, Drug Discovery, Forensic, Others), By End User (Pharmaceutical and Biotechnology Companies, Diagnostic Centers, Academic and Research Institutes) and Geography  

Digital PCR Market size was valued at USD 506.42 million in 2022 and is poised to grow at a significant CAGR of 9.2% from 2023-2029. Digital PCR (dPCR) is a newer PCR technology that has been used in molecular genetic analysis for the detection of cancer, mutational analysis, quantitative gene expression study, and evaluation of allelic imbalance. There is an urgent need to adopt cutting-edge diagnostic tools and therapies to help reduce the disease burden due to the rising incidence of infectious diseases and cancer around the world and the rise of rare cancer incidences. Due to the utilization of their novel applications in laboratories, it is anticipated that the global digital polymerase chain reaction market would experience a significant amount of opportunistic emphasis. In the continents of Asia and Africa, a surge in the demand for digital PCR from veterinary and medical microbiology is expected to fuel the market revenue over the forecast period. Furthermore, due to its higher efficacy and simplicity of use, clinical diagnostic applications of digital PCR are only anticipated to present an adaptive approach during the forecast period, propelling market expansion. New plant species identification, veterinary illness diagnostics, and animal species identification also use portable digital PCR. Therefore, a sizable pool of consumers is anticipated to be drawn to the plethora of applications of digital PCR in domains such as healthcare, food, environment, animal health, conservation, and forensics, aside from the detection of diseases. Additionally, it is projected that improvements in digital PCR technology and an increase in product launches on the worldwide market would support the development of the digital PCR business. For instance, one of the world's top companies in the life sciences sector, Bio-Rad Laboratories, Inc., announced the release of the prevalence dPCR SARS-CoV-2 wastewater quantification kit for COVID-19 wastewater testing in June 2021. Additionally, the expansion of collaboration agreements between businesses for the development of digital PCR and the surge in R&D activity for PCR technology advancement both contribute to the growth of the digital PCR industry. As an illustration, in January 2022, Qiagen, a well-known manufacturer of diagnostic tools, collaborated with Atila BioSystems and Actome GmbH to offer non-invasive prenatal testing (NIPT) options for QIAGEN's dPCR and license & co-marketing agreement.

Digital PCR Market Key Developments:

• On 22nd August 2022, Roche has launched its Digital LightCycler System, a digital PCR system, it will help to understand the patient's cancer, genetic disease, and infections. The Digital LightCycler System is Roche's first digital Polymerase Chain Reaction Device. It is going to be available in 15 countries in 2022.
• In February 2022, F. Hoffmann-La Roche Ltd expanded the COVID-19 PCR tests in countries accepting the CE market.
• In 2020, Bio-Rad received FDA emergency use authorization for the Droplet Digital PCR SARS-CoV-2 Test Kit.
• In 2020, Biomerieux S.A. received the CE Mark approval for SARS-CoV-2 R-GENE tests to include saliva specimens. The company also received emergency use authorization for the BioFire COVID-19 test.